Gab2-MALT1 signaling and venous clots: a new path to safer therapies
Official title: The Role of Gab2-MALT1-mediated cell signaling in venous thrombogenesis
Funded at University of Texas Hlth Ctr at Tyler · NIH-11326270 · Data updated 2026-11-12
A doctor-scientist team is studying how a specific cell signaling pathway (Gab2-MALT1) contributes to venous clots, with the aim of finding safer ways to prevent and treat them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Ctr at Tyler NIH-funded |
| Lab location | 1 site (Tyler, United States) |
| Project start | July 15, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $601,442 |
| NIH project number | 5R01HL170945-03 |
| Project ID | NIH-11326270 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with or at risk for venous thromboembolism (deep vein thrombosis or pulmonary embolism) who could benefit from safer clot-prevention strategies.
✕Less likely to help
Patients without venous thrombosis or those not affected by clot-promoting inflammation may not directly benefit.
What this research studies
This project looks at how blood vessels and inflammation contribute to dangerous clots in veins. The researchers are focusing on Gab2 and the CBM signalosome in endothelial cells to understand how clotting signals are turned on during inflammation. The goal is to identify targets that could lead to safer anticoagulant therapies with fewer bleeding risks. The study combines laboratory experiments with data from human biology to map how these signals promote clot formation.
Why it matters
Potential benefit: If successful, this work could lead to new therapies that prevent or treat venous clots with lower bleeding risk.
How similar studies have gone: Previous work suggests Gab2 and CBM signaling influence thromboinflammation, but translating this to safer therapies is still being explored.
Where this research is happening
-
University of Texas Hlth Ctr at Tyler
Tyler, United States Active
Researchers
- Principal investigator: Lella, Vijaya Mohan Rao — University of Texas Hlth Ctr at Tyler
- Study coordinator: Lella, Vijaya Mohan Rao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.